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Differences in cardiovascular disease are found between the genders. In women, it is known that estrogen
has both indirect and direct protective effects on the cardiovascular system. This includes a decrease in low-
density lipoprotein cholesterol (LDL-C), an increase in high-density lipoprotein cholesterol (HDL-C), the vasodilata-
tion response by endothelial Nitric Oxide Synthase (eNOS) synthase, and prostacyclin synthesis.
Many cases of coronary spastic angina and acute coronary syndrome (ACS) have been observed during the
menstrual and the late luteal phases of the menstrual cycle, corresponding with low levels of estrogen. After
menopause, the risk of atherosclerosis and associated conditions such as; dyslipidemia, hypertension, obesity, dia-
betes, T cell activation, and adhesion molecules, increase. Consequently, the risk of a cardiovascular event also in-
creases. In addition, regarding the pathological mechanism underlying ACS, erosion is observed most promi-
nently during pre-menopause, whereas plaque rupture is observed in post-menopause.
Furthermore, microvascular angina is often found in menopausal women displaying various symptoms, thus
a diagnosis may be difficult. We recognize a decrease in vascular endothelial function and the coronary flow re-
serve and a high level of lactic acid in the coronary sinus as diagnostic criteria. Regarding problems associated
with the“super-aging”society, there are many elderly female patients with HFpEF (heart failure with preserved
ejection fraction) who have diastolic dysfunction. Also well-known are cases of atherosclerosis and osteoporosis
progressed by common risk factors, and recently, vascular bone disease.
There are characteristics in women for microvascular angina and heart failure, as well as ischemic heart dis-
ease, due to atherosclerosis caused by the sex hormone environment in later life stages. Considering gender-
specific medicine in the prevention and treatment of cardiovascular disease is important for healthy aging of
women.
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蛋白である apolipoprotein fraction A-I（アポ AI）の
合成も促し，血中 HDL-C増加をもたらす．さらに，
















































Figure　1　The protective direct and indirect effects of estrogen.
eNOS, endothelial NO synthase; PI, prostacyclin; EDHF, endothelium-derived hyperpolar-

























Table　1　Physiological circulatory function and diseases in the menstrual cycle.
Menstrual phase Follicular phase Luteal phase
Physiological circulatory function Diastolic blood pressure ↓ Systolic blood pressure ↓
Diastolic blood pressure ↓
HR↓ HR↓
RPP↑




Disease Supraventricular tachycardia ↑ Vasospastic angina ↓
Idiopathic ventricular tachycardia↑ Effort angina pectoris ↓
Vasospastic angina ↑
Effort angina pectoris ↑
Acute coronary syndrome (ACS) ↑
Menstrual asthma ↑
Catamenial pneumothorax ↑
























































































































































































Figure　6　Characteristics of unstable plaque. Stable plaque has a thick fibrous cap, less 
lipid core, less inflamed cells and no thrombus. Whereas, unstable plaque contains a large 
lipid core with hemorrhage, neoangiogenesis, apoptosis of smooth muscle cells and endothe-




























Figure　7　Event-free survival from cardiovascular (CV) events by coronary artery disease 
(CAD) and persistent chest pain (PChP). CV events were defined as CV death, myocardial 

























































が主な病態である HFpEF（heart failure with pre-
served ejection fraction）が多く，予後は良い．男性
は左室拡大，EF＜40%の左室収縮能低下を呈する
HFrEF（heart failure with reduced ejection frac-
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